# Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

> **NCT02059239** · PHASE1,PHASE2 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 34 (actual)

## Conditions studied

- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Carmustine
- **DRUG:** Etoposide
- **DRUG:** Melphalan
- **DRUG:** Cytarabine
- **DRUG:** Alemtuzumab
- **BIOLOGICAL:** Autologous Stem Cell Transplantation
- **BIOLOGICAL:** Allogeneic Stem Cell Transplantation
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02059239
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-04
- **Primary completion:** 2019-12-16
- **Final completion:** 2020-06-15
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02059239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02059239, "Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02059239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*